ES2254422T3 - 4-bencil-1-(2-(4-hidroxi-fenoxi)-etil)-piperidin-3,4-diol. - Google Patents

4-bencil-1-(2-(4-hidroxi-fenoxi)-etil)-piperidin-3,4-diol.

Info

Publication number
ES2254422T3
ES2254422T3 ES01933833T ES01933833T ES2254422T3 ES 2254422 T3 ES2254422 T3 ES 2254422T3 ES 01933833 T ES01933833 T ES 01933833T ES 01933833 T ES01933833 T ES 01933833T ES 2254422 T3 ES2254422 T3 ES 2254422T3
Authority
ES
Spain
Prior art keywords
benzyl
piperidin
diol
ethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01933833T
Other languages
English (en)
Spanish (es)
Inventor
Alexander Alanine
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2254422T3 publication Critical patent/ES2254422T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES01933833T 2000-04-25 2001-04-17 4-bencil-1-(2-(4-hidroxi-fenoxi)-etil)-piperidin-3,4-diol. Expired - Lifetime ES2254422T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25
EP00108769 2000-04-25

Publications (1)

Publication Number Publication Date
ES2254422T3 true ES2254422T3 (es) 2006-06-16

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01933833T Expired - Lifetime ES2254422T3 (es) 2000-04-25 2001-04-17 4-bencil-1-(2-(4-hidroxi-fenoxi)-etil)-piperidin-3,4-diol.

Country Status (18)

Country Link
US (1) US6432985B2 (enExample)
EP (1) EP1278730B1 (enExample)
JP (1) JP3831255B2 (enExample)
KR (1) KR100527527B1 (enExample)
CN (1) CN1178914C (enExample)
AR (1) AR028357A1 (enExample)
AT (1) ATE313527T1 (enExample)
AU (1) AU785153B2 (enExample)
BR (1) BR0110233A (enExample)
CA (1) CA2407345C (enExample)
DE (1) DE60116080T2 (enExample)
DK (1) DK1278730T3 (enExample)
ES (1) ES2254422T3 (enExample)
MX (1) MXPA02010573A (enExample)
PE (1) PE20011229A1 (enExample)
UY (1) UY26681A1 (enExample)
WO (1) WO2001081309A2 (enExample)
ZA (1) ZA200208134B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP1585430B1 (en) 2002-11-14 2017-01-11 Brainsgate Ltd. Surgical tools and techniques for stimulation
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
AU2009228660B2 (en) * 2008-03-27 2012-11-29 Evotec International Gmbh Methods for treating disorders using NMDA NR2B-subtype selective antagonist
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
ES2463766T3 (es) * 2008-08-12 2014-05-29 Zinfandel Pharmaceuticals, Inc. Método de identificación de factores de riesgo de la enfermedad de Alzheimer
WO2012096873A1 (en) 2011-01-10 2012-07-19 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11319314B2 (en) 2016-11-08 2022-05-03 Hoffmann-La Roche Inc. Phenoxytriazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
DE60116080D1 (de) 2006-01-26
ATE313527T1 (de) 2006-01-15
BR0110233A (pt) 2003-01-21
US20010047014A1 (en) 2001-11-29
AU785153B2 (en) 2006-10-05
PE20011229A1 (es) 2001-12-08
KR100527527B1 (ko) 2005-11-09
CA2407345A1 (en) 2001-11-01
JP3831255B2 (ja) 2006-10-11
ZA200208134B (en) 2004-01-22
AU6021301A (en) 2001-11-07
AR028357A1 (es) 2003-05-07
CN1443166A (zh) 2003-09-17
DK1278730T3 (da) 2006-05-01
KR20040007216A (ko) 2004-01-24
EP1278730A2 (en) 2003-01-29
MXPA02010573A (es) 2003-03-10
WO2001081309A2 (en) 2001-11-01
US6432985B2 (en) 2002-08-13
CN1178914C (zh) 2004-12-08
WO2001081309A3 (en) 2002-01-17
EP1278730B1 (en) 2005-12-21
CA2407345C (en) 2009-04-07
JP2004509837A (ja) 2004-04-02
DE60116080T2 (de) 2006-08-24
UY26681A1 (es) 2001-10-25

Similar Documents

Publication Publication Date Title
ES2254422T3 (es) 4-bencil-1-(2-(4-hidroxi-fenoxi)-etil)-piperidin-3,4-diol.
ES2991028T3 (es) Compuesto de piperidina sustituida como agonista de tipo 2 de la orexina para el tratamiento de la narcolepsia
ES2230846T3 (es) 4-fenilpiperidinas para el tratamiento de la dermatosis de prurito.
US20070066584A1 (en) Amido compounds and their use as pharmaceuticals
US6790854B2 (en) Diphenylalkylamine derivatives useful as opioid receptor agonists
IL263752A (en) Training modulating compounds
BRPI0411713B1 (pt) Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
PT90619B (pt) Processo para a preparacao de compostos de piperazina
ES2393822T3 (es) Nuevos derivados de piperazina-amida
ES2364727T3 (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2,2-difenilhexanamida.
HUP0105108A2 (hu) Amidvegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2254183T3 (es) Derivados de etansulfonil-piperidina.
ES2248281T3 (es) Derivados de fenoxialquilamina utiles como agonistas del receptor opioide delta.
ES2235844T3 (es) Agentes antibacterianos.
ES2547415T3 (es) Derivados de oxiindol con actividad agonista del receptor de motilina
WO2001025199A1 (en) Urea compounds, process for producing the same and use thereof
CN100467449C (zh) 氨基磺酸环状氨基苯基酯衍生物
ES2359242T3 (es) Indazoles que presentan una actividad analgésica.
WO2025026392A1 (zh) 驱动蛋白kif18a抑制剂及其应用
ES2215688T3 (es) Nuevos derivados amida.
DE60312511T2 (de) Oxophenylcyclohexylpropanolaminderivate, deren herstellung und verwendung in therapeutika
ES2384574T3 (es) Derivado de piperidina o sal farmacéuticamente aceptable del mismo
JPH10500967A (ja) カルシウムチャンネルアンタゴニストとしてのフェノキシアルキル置換ピペリジン、ピロリジン、モルホリンおよびチオモルホリン
BRPI0609312A2 (pt) cicloexano-1,4-diaminas substituìdas por piperidinila
JPWO2001021169A1 (ja) Ｍｃｈ拮抗剤